Jonathan Janes

6.2k citations

50 papers · 3.7k indexed · 3 hit papers · h-index 25

Critical Care and Intensive Care Medicine top 0.5%
- Intensive Care Unit Cognitive Disorders 5
Dermatology top 0.5%
- Dermatology and Skin Diseases 10
Immunology and Allergy top 1%
- Allergic Rhinitis and Sensitization 6
- Food Allergy and Anaphylaxis Research 4
Rheumatology top 1%
- Systemic Lupus Erythematosus Research 4
Epidemiology top 2%
- Sepsis Diagnosis and Treatment 25
Surgery
- Hemodynamic Monitoring and Therapy 7
Public Health, Environmental and Occupational Health
- Neonatal and Maternal Infections 5

Co-authors: William L. Macias Antonio Artigas Jean-François Dhainaut Mark D. Williams Amy M. DeLozier Ivor S. Douglas Fabio P. Nunes Burkhard Vangerow
Cited by: Critical Care and Intensive Care Medicine Dermatology Immunology and Allergy
Journals: Critical Care (12 papers)Journal of the American Academy of Dermatology (4 papers)Critical Care Medicine (4 papers)
Partner nations: United States Germany United Kingdom

In The Last Decade

Jonathan Janes

50 papers receiving 3.6k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2018 The Lancet
2018 Journal of the American Academy of Dermatology
2012 New England Journal of Medicine

Peers

Countries citing papers authored by Jonathan Janes

Since Specialization

Citations

This map shows the geographic impact of Jonathan Janes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Janes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Janes more than expected).

Fields of papers citing papers by Jonathan Janes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Janes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Janes. The network helps show where Jonathan Janes may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jonathan Janes, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jonathan Janes Line = papers co-authored together Jonathan Janes links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3 British Journal of Dermatology ·Kristian Reich,Eric L. Simpson,Andreas Wollenberg,Robert Bissonnette,Masatoshi Abe,Tracy Cardillo,Jonathan Janes,Luna Sun,Naufal Dyas Anggara Faza,Jonathan I. Silverberg	2022	11
2	Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5) Journal of the American Academy of Dermatology ·Eric L. Simpson,Seth Forman,Jonathan I. Silverberg,Matthew Zirwas,Emanual Maverakis,George Han,Emma Guttman‐Yassky,P. Dziadczyk,Robert Bissonnette,Jill Waibel,Fabio P. Nunes,Amy M. DeLozier,Siyu Yang,Margaret Gamalo,Katrin Holzwarth,Orin M. Goldblum,Jinglin Zhong,Jonathan Janes,Kim Papp	2021	106
3	Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study Journal of the American Academy of Dermatology ·Brett King,Justin Ko,Seth Forman,Manabu Ohyama,Natasha Atanaskova Mesinkovska,Guanglei Yu,Jill Shwed McCollam,Margaret Gamalo,Jonathan Janes,Emily Edson‐Heredia,Katrin Holzwarth,Yves Dutronc	2021	90
4	Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose studybreakdown → Journal of the American Academy of Dermatology ·Emma Guttman‐Yassky,Jonathan I. Silverberg,Osamu Nemoto,Seth Forman,A Wilke,Randy Prescilla,Amparo de la Peña,Fabio P. Nunes,Jonathan Janes,Margaret Gamalo,David W. Donley,Jim S Paik,Amy M. DeLozier,Brian J. Nickoloff,Eric L. Simpson	2018	250
5	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trialbreakdown → The Lancet ·Daniel J. Wallace,Richard Furie,Yoshiya Tanaka,Kenneth Kalunian,Marta Mosca,Michelle Petri,Thomas Dörner,Mario H. Cardiel,Ian N Bruce,Elisa Gómez,Tara Carmack,Amy M. DeLozier,Jonathan Janes,Matthew D. Linnik,Stephanie de Bono,Maria Silk,Robert W. Hoffman	2018	356
6	Beyond single-marker analyses: mining whole genome scans for insights into treatment responses in severe sepsis The Pharmacogenomics Journal ·M. Man,Sandra Close,Andrew Shaw,Gordon R. Bernard,Ivor S. Douglas,Sun-hoo Na,Didier Payen,Jean‐Louis Vincent,Зотов Алексей Николаевич,Jonathan Janes,Upvan Narang,Lee A. O’Brien,Mark D. Williams,Joe G. N. Garcia	2012	27
7	Drotrecogin Alfa (Activated) in Adults with Septic Shockbreakdown → New England Journal of Medicine ·V. Marco Ranieri,Bruce Thompson,Philip S. Barie,Jean-François Dhainaut,Ivor S. Douglas,Simon Finfer,Bengt Gårdlund,John C. Marshall,Andrew Rhodes,Antonio Artigas,Didier Payen,Jyrki Tenhunen,Hussein R. Al‐Khalidi,Vivian P. Thompson,Jonathan Janes,William L. Macias,Burkhard Vangerow,Mark D. Williams	2012	877
8	Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism Critical Care ·Carl-Erik Dempfle,Elif Elmas,Andreas Link,Suwito suwito,Volker Liebe,Jonathan Janes,Martin Borggrefe	2011	1
9	Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated) Critical Care ·Andrew F. Shorr,Jonathan Janes,Antonio Artigas,Jyrki Tenhunen,Duncan Wyncoll,Emmanuelle Mercier,Bruno François,Jean‐Louis Vincent,Burkhard Vangerow,Darell Heiselman,Upvan Narang,Yajun Emily Zhu,Konrad Reinhart,Ford Helen	2010	14
10	Global utilization of low-dose corticosteroids in severe sepsis and septic shock: a report from the PROGRESS registry Critical Care ·Richard Beale,Jonathan Janes,Frank M. Brunkhorst,Geoffrey Dobb,Mitchell M. Levy,Greg S. Martin,Graham Ramsay,Eliezer Silva,Charles L. Sprung,B. Vallet,Jean‐Louis Vincent,Timothy M. Costigan,Upvan Narang,Mark D. Williams,Konrad Reinhart	2010	58
11	Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis Critical Care ·Pierre‐François Laterre,William L. Macias,Jonathan Janes,Mark D. Williams,David R. Nelson,E. Letavernier,Jean-François Dhainaut,Edward Abraham	2008	10
12	Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated) Critical Care ·Andrew F. Shorr,David R. Nelson,Duncan Wyncoll,Konrad Reinhart,Frank M. Brunkhorst,G. Matthew Vail,Jonathan Janes	2008	30
13	Prophylactic Heparin in Patients with Severe Sepsis Treated with Drotrecogin Alfa (Activated) American Journal of Respiratory and Critical Care Medicine ·Marcel Levi,Mitchell M. Levy,Mark D. Williams,Ivor S. Douglas,Antonio Artigas,Massimo Antonelli,Duncan Wyncoll,Jonathan Janes,Frank V. McL. Booth,Dazhe Wang,David P. Sundin,William L. Macias,(unknown)	2007	107
14	ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: One-year safety and efficacy evaluation* Critical Care Medicine ·Pierre‐François Laterre,Edward Abraham,Jonathan Janes,Benjamin Trzaskoma,B. Spalding-Yoder,Frank V. McL. Booth	2007	27
15	The protein C pathway: implications for the design of the RESPOND study Critical Care ·Burkhard Vangerow,Andrew F. Shorr,Duncan Wyncoll,Jonathan Janes,David R. Nelson,Konrad Reinhart	2007	13
16	Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment* Critical Care Medicine ·Jean‐Louis Vincent,Gordon R. Bernard,Richard Beale,Christopher J. Doig,Christian Putensen,Jean-François Dhainaut,Antonio Artigas,Roberto Fumagalli,William L. Macias,Theressa J. Wright,Kar Wong,David P. Sundin,Miriam Ascarelli,Jonathan Janes	2005	219
17	DATA FROM THE TOP TEN ENROLLING COUNTRIES CONTAINED IN THE PROGRESS (PROMOTING GLOBAL RESEARCH EXCELLENCE IN SEVERE SEPSIS) REGISTRY DEMONSTRATES VARIATIONS IN TREATMENT AND HIGH MORTALITY RATES CHEST Journal ·Konrad Reinhart,Jean‐Louis Vincent,Graham Ramsay,晨韵,Eliezer Silva,Richard Beale,Frank M. Brunkhorst,Mitchell Levy,Greg S. Martin,Miriam Ascarelli,Samiha Sarwat,Jonathan Janes	2005	1
18	THE SAFETY OF DROTRECOGIN ALFA (ACTIVATED): INDEPTH DATA ANALYSIS SUGGESTS SURVIVAL BENEFIT INDEPENDENT OF SERIOUS ADVERSE EVENT OCCURRENCES CHEST Journal ·Robert L. Levine,S. C. Lowry,Jean-François Dhainaut,Pierre‐François Laterre,Gregory J. Beilman,I. Alan Fein,Anna Huen,Jonathan Janes,David R. Nelson,X. Chen,Frank Booth,Michael C. Meyer	2005	1
19	Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial Intensive Care Medicine ·Jean-François Dhainaut,Pierre‐François Laterre,Jonathan Janes,Gordon R. Bernard,Antonio Artigas,Jan Bakker,Hanno Riess,Bruce R. Basson,Julien Charpentier,Barbara G. Utterback,Jean‐Louis Vincent,(unknown)	2003	109
20	An assessment of the ability of impedance respirometry distinguish oesophageal from tracheal intubation Anaesthesia ·Allan Vidal de Negreiros,Andrew Turley,A McDaniel,Jonathan Janes,Judith E. Hall	2002	20

About Jonathan Janes

Jonathan Janes is a scholar working on Critical Care and Intensive Care Medicine, Dermatology and Immunology and Allergy, having authored 50 papers that have together received 3.7k indexed citations. Recurring topics across this work include Sepsis Diagnosis and Treatment (25 papers), Dermatology and Skin Diseases (10 papers), Hemodynamic Monitoring and Therapy (7 papers), Allergic Rhinitis and Sensitization (6 papers), Intensive Care Unit Cognitive Disorders (5 papers), Neonatal and Maternal Infections (5 papers), Systemic Lupus Erythematosus Research (4 papers) and Food Allergy and Anaphylaxis Research (4 papers). The work is most often cited by research in Critical Care and Intensive Care Medicine (506 citations), Dermatology (821 citations) and Immunology and Allergy (517 citations). Jonathan Janes has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include William L. Macias, Antonio Artigas, Jean-François Dhainaut, Mark D. Williams, Amy M. DeLozier, Ivor S. Douglas, Fabio P. Nunes, Burkhard Vangerow, Didier Payen and Jyrki Tenhunen. Their work appears in journals such as Critical Care, Journal of the American Academy of Dermatology, Critical Care Medicine, British Journal of Dermatology and Intensive Care Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact